Clinics in Laboratory Medicine 2002: Vol 22 Index

31 Pages·2002·4.5 MB·English

CLINICS IN
S LABORATORY
MEDICINE
Clin Lab Med 22 (2002) 1021-1050 ACD
Subject Index to Volume 22
Volume 22
March INTERPRETATION OF THE PERIPHERAL BLOOD FILM, pages 1-356
June TEST SELECTION STRATEGIES, pages 357-572
September CLINICAL HIV-1 VIROLOGY, pages 573-834
December EMERGING AND RE-EMERGING INFECTION DISEASES,
pages 835-1050
Note: Page numbers of article titles are in boldface type.
A bone marrow examination in, 170
Abacavir, for HIV infection, complications classification of, 170-180, 189
of. 748 clinical features of, 169
course of, 183
Abciximab, thrombocytopenia due to, cytogenetics of, 180-182
198-199 diagnosis of, 156-158
Acanthocvtes. 48-49. 54 differential diagnosis of, 180
9 erythroleukemia, 175
Acute lymphoblastic leukemia, 158-169 etiology of, 155
aplastic, 185 hypocellular, 187
bilineal, 183 in familial platelet disorder,
biphenotypic, 183 203-204
blood film findings in, 159, 337 incidence of, 169
bone marrow examination in, 159, 161 laboratory findings in, 169-170
classification of, 159-161 megakaryoblastic, 175-176,
clinical features of, 159 179-186
course of, 168 monocytic, 174—175, 178
cytochemistry in, 162 myeloblastic, 170-172
cytogenetics of, 164-167 myelomyocytic, 173-174, 177
diagnosis of, 157-158 promyelocytic, 172-173
differential diagnosis of, 168 therapy-related, 184
etiology of, 155 treatment of, 183
granular, 185 trilineage dysplasia with, 184
hypocellular, 185 ‘ ; ;
immunophenotyping in, 162-164 Adenosine diphosphate, in platelet
incidence of, 158-159 aggregation evaluation, 409-411
laboratory findings in, 159 Adenoviruses, as HIV vaccine vectors,
mixed-phenotype, 183 807-808
molecular diagnosis of, 164 :
terminal deoxynucleotidyltransferase Adhesion, platelet, 406-407
in, 162 Adrenocorticotropic hormone,
treatment of, 168-169
measurement of, in Cushing’s
versus acute myeloid leukemia, 180 syndrome, 428-430
with t(4;11), 185
: African trypanosomiasis, 269-271
Acute myeloid leukemia, 169-183
bilineal, 183 Agglutination, red cell, in blood films, 57,
biphenotypic, 183 225
pa aa ‘
blood film findings in, 169-170 Aggregation, platelet, 407, 409-413
0733-8619/02/$ - see front matter © 2002, Elsevier Science (USA). All rights reserved.
PII: S0733-8619(02)00026-9
1022 Subject Index | Clin Lab Med 22 (2002) 1021-1050
Agnogenic myeloid metaplasia, chronic, Angioimmunoblastic lymphadenopathy,
peripheral blood findings in, with dysproteinemia, 242
143-146
Angiotropic lymphoma, 240
AIDS dementia. See Central nervous
Animal cracker cells, 51-52, 54
system, HIV infection of.
Anisocytosis, 30-31
Alanine aminotransferase, in liver disease
in necrosis, 379-380, 385 Annulocytes, 36
in specific diagnosis, 385-387
Antibiotic susceptibility testing, of
Albumin, synthesis of, indicators of, nontuberculous Mycobacterium, 917
381-382, 386
Antibody(ies)
Alcohol, thrombocytopenia due to, 199 antinuclear, testing of. See Antinuclear
antibody testing.
Aldosteronism, primary, endocrine test
Bartonella, 942-943
strategies for, 430-433
blocking, to intrinsic factor,
Alkaline phosphatase, in cholestasis, 378, measurement of, 437-438
380-381, 385-387 HIV. See Human immunodeficiency
virus, antibodies to.
ALL. See Acute lymphoblastic leukemia. influenza virus, 873-874
Alpha naphthyl esterases, for acute specific, in HIV cell entry, 687
leukemia diagnosis, 156—157 synthesis of, indicators of, 382
Alphaviruses, as HIV vaccine vectors, 808 Anticentromere antibodies, testing for,
456-457
ALX40-4C (CXCR4 antagonist), for HIV
infection, 691-692 Anticoagulants, for blood films, 3-4
Amantadine, for influenza, 877-878 Antigen-induced cell death, 775-776
AMD3100 (CSCR4 antagonist), for HIV Antigen-presenting cells
infection, 692 function of, 774-776
HIV-specific, for HIV infection, 785
Aminotransferases
subsets of, in immune reconstitution,
in liver cell necrosis, 379-380, 385 725-726
in specific diagnosis, 385-387
Antigenic assay, for protein C deficiency,
AML. See Acute myeloid leukemia. 398
ANA testing. See Antinuclear antibody Antinuclear antibody testing, 447-474
testing. cutoff dilution for, 458-459
Anemia(s) enzyme immunoassay, 460-466
classification of, 33 follow-up testing in, 468-469
by reticulocyte count, 77—78 indications for, 466-469
hemolytic indirect immunofluorescence, 448-460,
in infections, 260 464 466
spherocytes in, 38-39 lupus erythematosus cell test in,
hyperchromatic, 32 448-449
in chronic disease, 216 optimum strategy for, 466
in lymphoma, 216 overuse of, 468
iron deficiency, 36—37 patient selection for, 466-469
macrocytic, 34-35 proficiency testing in, 459
microcytic hypochromic, 36-38
Antioxidants, neuroprotective effects of, in
pernicious. See Vitamin B,> deficiency. HIV infection, 711
reticulocyte count correction for, 70
spur cell (acanthocytosis), 48-49 Antiretroviral agents, for HIV infection,
treatment of, reticulocyte count in, 741Se-e a7lso 5spec7ific. dru gs.
76-77 adherence to, 747-748, 765-766
versus pseudoanemia, 95 antiviral effects of, 746-747
combinations of, 745, 753-754. See
Angina, myocardial damage markers in. See
also HAART (highly active
Myocardial damage markers. antiretroviral therapy).
Subject Index | Clin Lab Med 22 (2002) 1021-1050
complications of, 748-749, 764-765 Arbitrarily primed polymerase chain
cross-resistance in, 640-644, 749-750 reaction, for Bartonella, 948
efficacy of, 601-603
entry inhibitors, 681-701 Arenaviruses, 979, 983. See also individual
failure of, 645, 753-754 diseases.
future of, 754-755 natural reservoirs of, 986-987
transmission of, 987
highly active therapy with. See
HAART (highly active Argentine hemorrhagic fever
antiretroviral therapy). control of, in community, 1010
hypersusceptibility of, 643 geographic distribution of, 984
immunologic effects of, 746-747 overview of, 980
in pediatric patients, 764-767
Artifacts
in perinatal transmission prevention,
761 in blood films, 81-100
initiation of, 750-751 causes of, 82
interrupted therapy with, CD8+ T classification of, 82-83
lymphocytes and, 782-784 cryoprotein precipitation,
mechanisms of action of, 743-745 89-90
minority virus populations in, 638 degenerating necrobiotic cells,
220, 223
modification of regimes, 753-754
monitoring of, 579-580, 751-753 glass effect, 94
pathogenesis and, 741-743 in lymphoma, 220
penetration of barriers by, 658-659 investigation of, 82
pharmacokinetics of, in pediatric preparation-related, 7
patients, 766 pseudo Bernard-Soulier
resistance to, 637-649, 749-750 syndrome, 87
assays for, 637-640 pseudo Chédiak-Higashi
clinical testing for, 644-645 abnormality, 88-89
cross-resistance in, 640-644, pseudo gray platelet syndrome,
749-750 87
genotypic assays for, 637-638, pseudo Pelger-Huét anomaly, 88
644 pseudo polycythemia, 94-95
heterotypic, 750 pseudoanemia, 95
in CCRS mutations, 691 pseudoechinocytosis, 94
in nucleoside analogue pseudoleukemia, 92-93
mutations, 641-643 pseudoleukocytosis, 89-90
in pediatric patients, 767 pseudoleukopenia, 91-92
phenotypic assays for, 638-639, pseudothrombocytopenia, 83-86,
194-195
644-645
testing of, 752-753 pseudothrombocytosis, 86-87
viral load and, 749-750 pseudotoxic changes, 93
susceptibility testing of, 752-753 satellitism, 85-86
thymidine analogue mutations in, 641 smudge cells, 220, 222
viral load and, 582, 601-604 surfactant effect, 48, 95-96
in red cell morphology, 42-47
%,-Antitrypsin deficiency, indicators of, 384 surfactant-related, 48, 95-96
Antiviral agents, for influenza, 875-879 Artificial intelligence systems. See Expert
systems.
Antivirogram assay, for HIV resistance, 639
Aspartate aminotransferase
Aplastic leukemia, acute lymphoblastic, 185
in liver cell necrosis, 379-380, 385
Apoptosis, of neurons, in HIV infection, in specific diagnosis, 385-387
705-706
Aspartate transferase:alanine
Appendicitis, band neutrophil count in, 109, aminotransferase ratio, in specific
114-115 diagnosis, 385-387
Arachidonic acid, in platelet aggregation Aspirin, platelet dysfunction due to,
evaluation, 411 415-416
1024 Subject Index | Clin Lab Med 22 (2002) 1021-1050
Atherosclerosis, myocardial damage reference ranges for, 103-105
markers in. See Myocardial damage
Bartonella, 935-960
markers.
culture of, 937-940, 952-953
Automated hematology analyzer, checking DNA hybridization tests for, 949
results of. See Review, blood film. gene sequence analysis of, 949
infections due to, 935-937
Automated image processing, for blood cell
antibody response in,
morphology identification, 299-315 942-943
first generation (stand-alone
enzyme immunoassay in, 946
instruments), 301-303
in immunodeficiency, 937
future, 310-312
indirect fluorescent antibody test
historical background of, 299-301
in, 943-947
review of. See Review, blood film.
lymph node examination in,
second generation (with slide maker
950-951
and stainer), 303-307
serologic tests for, 939, 941-947
third generation (with communication
molecular identification of, 947-954
network), 307-310
new species of, 936-937
Automated specific treponemal test, for polymerase chain reaction for,
syphilis, in donor blood, 481 948-954
restriction fragment length
Azidothymidine. See Zidovudine. polymorphism analysis of,
948-949
B
Bartonella bacilliformis
B-cell lymphoma culture of, 939
intravascular large, 240
infections due to, 935-936, 946-947
monocytoid, 240
splenic marginal zone, 245 Bartonella grahamii infections, 936
B lymphocytes, activation of, HAART Bartonella henselae
effects on, 729 antigens of, 941-942
culture of, 937-940
Babesiosis, 268-269
infections due to, 935, 937
Bacillary angiomatosis, diagnosis of, clinical studies of, 949-953
951-952 enzyme immunoassay in, 946
indirect fluorescent antibody test
BACTEC system, for nontuberculous in, 943-946
Mycobacterium, 912-913 serologic tests for, 939, 941-946
Bacterial vectors, for HIV vaccines, 806 Bartonella quintana
Band neutrophils, 101-136 antigens of, 941-942
counting of culture of, 937-940
alternatives to, 130 infections due to, 935, 937
evaluation of, 106—109 clinical studies of, 951-953
in appendicitis, 109, 114-115 indirect fluorescent antibody test
in infections, 109-112, 130 in, 943-945
in pediatric patients, 113-130 serologic tests for, 939, 941-946
from three to 36 months Basophilia, in lymphoma, 228
old, 113, 119-121
in sickle ceil disease, 113, Basophilic leukemia, acute, 186, 188
118
Basophilic stippling, or red cells, 59
less than three months old,
122-125 Bernard-Soulier syndrome, 202-203
newborn, 123, 126-130 platelet dysfunction in, 416
of mixed ages, 113, 116-117 versus pseudo Bernard-Soulier
likelihood ratios of, 108-109 syndrome, 87
technical limitations of, 105—106
Bicylcams, for HIV infection, 692
definition of, 103
left-shifted, 102 Bilirubin
pathophysiology of, 102-103 in cholestasis, 378
Subject Index | Clin Lab Med 22 (2002) 1021-1050 1025
metabolism of, indicators of, 381, Branched-chain DNA assay, for HIV, 580,
386-387 594-595
Bleeding time, in platelet function Brazilian hemorrhagic fever
evaluation, 409 geographic distribution of, 984
overview of, 981
Blocking antibody, to intrinsic factor,
measurement of, 437-438 Breast-feeding, HIV transmission in, 600,
760
Blood culture, cost effective methods for,
495 Brugia malayi infections, 271
Blood donor screening Buffy coats, for lymphoma and leukemia
for HIV, viral load testing in, 604-605 diagnosis, 229
for prion diseases, 858
Bunyaviruses, 981-982. See also individual
Blood films, peripheral. See Peripheral diseases.
blood films.
Burkitt’s lymphoma, 244-245
Blood glucose measurement
Burr cells, 51-52, 54
in diabetes mellitus diagnosis, 421-422
in hypoglycemia, 423-425
noninvasive, 550-553
c
Blood transfusions
blood testing before. See C peptide, measurement of, in
Pretransfusion blood testing. hypoglycemia, 424-425
human herpesvirus 8 transmission in,
C-reactive protein, measurement of, i
890 infection, 130
purpura after, thrombocytopenia in,
200-201 Cabot’s rings, in red cells, 59-60
BloodLink knowledge support tool, for Cameras, digital. See Digital technology,
expert systems, 523-524 for blood films, cameras.
Blood:testis barrier, antiretroviral agent Canadian health system, 505-514
penetration of, HIV persistence and, claw back formula in, 507-508
658 clinical practice guidelines of, 509-513
cost sharing in, 507-508
Boat method, of blood film staining, 20-21
fee setting in, 506-507
Bolivian hemorrhagic fever laboratory requisition forms of,
control of, in community, 1010 508-509
geographic distribution of, 984 laboratory services consolidation in,
overview of, 980 506
ordering protocols of, 509-513
Bone marrow origin of, 505
examination of physician audit in, 513
in acute lymphoblastic leukemia,
159 Canarypox virus, as HIV vaccine vector,
in acute myeloid leukemia, 170 806, 969-970
fibrosis of, in lymphoma, 225, 227
Cancer, solid tumors in. See Solid tumors.
replacement of, in malignancy, 225,
997 Candidiasis, blood film findings in, 266
Borrelia infections, 263-264 Capillary tubes, for blood film
preparation, 4
Bovine spongiform encephalopathy, variant
Creutzfeldt-Jakob disease and, Carbonic anhydrase, as myocardial damage
850-853, 857-858 marker, 361
Brain, HIV infection of. See Central Carcinocythemia, 245
nervous system, HIV infection of. pseudoleukemia in, 93
Brain nairiuretic peptide, as myocardial Carcinoma, solid tumors in. See Solid
damage marker, 362 tumors.
1026 Subject Index | Clin Lab Med 22 (2002) 1021-1050
Cardiac markers. See Myocardial damage Chest pain, myocardial damage markers in.
markers. See Myocardial damage markers.
Cardiac troponin, as myocardial damage Cholestasis, indicators of, 378-381, 385-386
marker, 360-361, 364-368
Cholesterol, in HIV cell entry, 687-688
Castleman’s disease, 888, 895
Cholesterol esterase, for acute leukemia
Cat scratch disease. See Bartonella henselae, diagnosis, 156-157
infections due to.
Chromatography, for nontuberculous
Cell antiviral factors, in HIV infection Mycobacterium identification, 916-917
resistance, 777
Chromosomal abnormalities, acute
Central nervous system, HIV infection of, leukemia in, 155-156, 158, 164, 168
703-717
Chronic wasting disease, encephalopathy in,
apoptosis-inducing factors in, 708-710
850
Env protein in, 707-708
macrophage involvement in, 706-707 Cidofovir, for Kaposi’s sarcoma, 896
pathology of, 705-706
protection of, 710-712 Clinical practice guidelines
viral reservoir in, 704-705 expert systems combined with,
523-525
Centromere, antibodies to, testing for, of Canadian health system, 509-513
456-457
Clopidogrel, platelet dysfunction due to,
Cerebrospinal fluid 416
analysis of, in infections, 493-494
as HIV reservoir, 704-705 Clostridium perfringens infections,
HIV load in, 600 hemolytic anemia in, 260
Cervicovaginal fluid, HIV load in, 600 Clot retraction test, of platelet function, 413
Chagas’ disease, 269-270 Coagulation. See a/so Protein C-protein S
pathway.
Cheédiak-Higashi abnormality, versus platelet function in, 407-409, 411-413,
pseudo Chédiak-Higashi abnormality, 417
88-89
Codocytes, 36
Chediak-Higashi syndrome, dense granule
storage pool deficiency in, 417 Cold agglutination disease
in lymphoma, 225
Chemicals, acute leukemia due to, 155 in Mycoplasma pneumoniae infections,
260
Chemokine receptor CCRS, in HIV
infection Collagen, in platelet aggregation evaluation,
in entry, 682, 684, 686-687 411-412
inhibitors of, 690-691
macrophages using, 706-707 Communication, of blood film information,
polymorphisms of, HIV transmission automated image processing systems
and, 761-762 for, 307-310
T lymphocytes tropism for, HIV Communication, Web in. See Web
latency and, during HAART, technology.
655-656
Complement, in HIV cell entry, 687
Chemokine receptor CXCR4, in HIV
infection Complete blood count protocol, of
in entry, 684, 686-687, 689 Canadian health system, 509-510
inhibitors of, 691-692
Coniide home sample collection kit, for
Chemotherapy HIV, 576
acute leukemia caused by, 155, 184 Congenital thrombocytopenia, 202
for acute leukemia
lymphoblastic, 168-169 Copper accumulation, in Wilson’s disease,
myeloid, 183 indicators of, 384
Subject Index | Clin Lab Med 22 (2002) 1021-1050
Coronary artery disease, myocardial Cytochemistry, for acute leukemia,
damage markers in. See Myocardial 156-157, 162
damage markers.
Cytogenetics, of acute leukemia, 158
Corticosteroid excess, in Cushing’s lymphoblastic, 164
syndrome, measurement of, 427-430 myeloid, 180-182
Cortisol excess, in Cushing’s syndrome, Cytokines, for HIV infection, 730-731,
784-785
measurement of, 427-430
Cost effectiveness Cytomegalovirus
of expert systems, 522-523 infections due to, 271-274
of microbiology tests, 494-496 testing for, in donor blood, after
pathogen inactivation, 484
Coverglasses, for blood films, 3, 5—6, 66
Cytotoxic T lymphocytes. See T
Creatine kinase, as myocardial damage
lymphocytes, CD8+ (cytotoxic).
marker, 358-359, 364—365, 367
Creutzfeldt-Jakob disease
D
epidemiology of, 849-850, 859-860
surveillance for, 858-860 Dacryocytes, 49
testing for, in donor blood, 476,
Decision-making, principles of, applied to
485-486
microbiology, 499-500
variant. See Variant Creutzfeldt-Jakob
disease. Degenerating necrobiotic cells, in blood
versus variant form, 856-857 films, 220, 223
Crimean-Congo hemorrhagic fever Delavirdine, for HIV infection, resistance
clinical features of, 998 to, 642
laboratory findings in, 998, 1007
Dementia, AIDS. See Central nervous
overview of, 982
system, HIV infection of.
pathology and pathogenesis of, 996
virology of, 985 Dendritic cells
function of, 774-776
Cross-resistance, of antiretroviral agents, in
HIV persistence in, 665
HIV infection, 640-644, 749-750
HIV-specific, for HIV infection, 785
Cryoprotein precipitation, in HIV cell entry, 687-689
pseudoleukocytosis in, 89-90 subsets of, in immune reconstitution,
725-726
Cryptococcosis, 267
Dengue fever and dengue hemorrhagic fever
Culture
classification of, 1001
for donor blood bacterial detection,
clinical features of, 997-998
484
control of, in community, 1009-1010
of Bartonella, 937-940
geographic distribution of, 984, 986
of HIV, 578, 584, 625-626
laboratory findings in, 1000, 1006
of influenza virus, 870
natural reservoirs of, 986
of nontuberculous Mycobacterium,
overview of, 980
911-913
pathology and pathogenesis of, 991,
Cushing’s syndrome, endocrine test 993
strategies for, 427-430 transmission of, 986
virology of, 985
Cyclophilin A, in HIV cell entry, 687
Dense granule storage pool deficiency,
Cyclospora cayetanensis, 925-934 platelet dysfunction in, 417
discovery of, 925-926
infection due to Dexamethasone suppression test, in
epidemiology of, 928-929 Cushing’s syndrome, 429-430
laboratory tests for,
Diabetes mellitus, endocrine test strategies
929-932 for, 421-422
pathogenesis of, 927-928
life cycle of, 926-927 Didanosine, complications of, 748
1028 Subject Index | Clin Lab Med 22 (2002) 1021-1050
DiffMaster system, for automated image Drugs
processing, 308 acute leukemia due to, 155
thrombocytopenia due to, 197-199
Digital technology, for blood films, 317-345
advantages of, 318, 339-340 Dutch College of General Practitioners,
applications of, 340-342 computer-based test ordering system
cameras of, 536-537
image sensors, 318
Dysproteinemia, with angioimmunoblastic
practical aspects of, 325
lymphadenopathy, 242
334-335
principles of, 318—3
still, 324, 326-329
technique for, 318 E
theory of, 318 Ebola hemorrhagic fever
types of, 323 clinical features of, 999
video, 324 laboratory findings in, 998, 1008
images overview of, 982
characteristics of, 320-321 pathology and pathogenesis of, 996
electronic publishing of, virology of, 985
338-339
printing of, 339-340 Eccentrocytes, 41-42
sensors for, 318-322 Echinocytes, 42-43
software modification of,
336-338 Echinocytosis, versus pseudoechinocytosis,
storage of, 322-324 94
in research, 342
Education, hematology, digital technology
value-added pathology reports in,
341-342 for, 340
Efavirenz, for HIV infection, resistance to,
Dilutional thrombocytopenia, 196
642
Directigen Flu tests, 872
Ehrlichiosis, 264 265
Discrepant analysis, in microbiology,
Electrocardiography, in myocardial
496-497
damage, biochemical testing with, 362
Disseminated intravascular coagulation, 363
thrombocytopenia in, 200
Electron microscopy
DNA, HIV for acute leukemia, 157
as viral reservoir, 653-654 of platelets, 194
in vaccine preparation, 804-805,
Electronic publishing, of blood film images,
970-972
338-339
DNA analysis
Electrophoresisf,o r Bartonella
for activated protein C resistance,
identification, 949
394-395
for acute leukemia, 158, 164, 168 ELISA. See Enzyme-linked immunosorbent
for nontuberculous Mycobacterium, assay.
913-915
for platelet function evaluation, 414 Elliptocytes, 39
Dohle bodies, in neutrophils, in infections, Encephalitis, in HIV infection, pathology
254 of, 705-706
Double-antigen sandwich assays, for HIV, Encephalopathy, bovine spongiform
574 encephalopathy, variant Creutzfeldt-
Jakob disease and, 850-853, 857-858
Doughnut cells (torocytes), 46-47
Endocarditis, Bartonella, 936-937, 951-953
Downey type II cells, in infectious
mononucleosis, 256—257 Endocrine test strategies, 421-434
for Cushing’s syndrome, 427-430
DP178 (T-20) antiretroviral agent, for HIV for diabetes mellitus, 421-422
infection, 692-693, 754 for hypoglycemia, 423-424
Subject Index | Clin Lab Med 22 (2002) 1021-1050 1029
for primary aldosteronism, 430-433 approaches of, 517
for thyroid dysfunction, 424-427 BloodLink guidelines in, 523-524
cost of, 522-523
Enterobacterial repetitive intergenic
database record of, 525
consensus polymerase chain reaction,
development of, 515-51
for Bartonella, 948
diagnostic accuracy of,
env gene and protein, HIV, 612-614
in entry, 683-685 9 5
in neurotoxicity, 707-708 ordering module of, 518
recombinant, in vaccine preparation, protocols of, 523-525
803-804 result review in, 520-521
structure of, 683 second-round test orders in, 521
use of, 522-523
Enzyme immunoassay, for antinuclear
antibodies, 460-466 Extractable nuclear antigens, in antinuclear
negative predictive value of, 463-465 antibody testing, 453-454
procedure for, 461
Eyecount leukocyte differential count
sensitivity and specificity of, 462-466
automation of, history of, 280-284
versus indirect immunofluorescence
errors in, 284—287
test, 464-466
evaluation of, 289-290
Enzyme-linked immunosorbent assay indications for, automated system
for HIV, 573-575 flagging criteria for, 290-293
antigen capture with, for p24 reference method for, 285, 288
antigen detection, 577-578 restrictions of, 293-295
home sample collection kit for,
Eyecount reticulocyte count
576
characteristics of, 66
rapid version of, 575-576
correction for anemia, 70
for human herpesvirus 8, 885-887
cost analysis of, 71
for influenza virus, 873
errors in, 68-69
for viral hemorrhagic fevers, 1004,
precision of, 69
1006-1008, 1011 reference values for, 70—71, 74-75
Eosin, in Wright-Giemsa stain, 16-18 slide examination before, 67-68
stains for, 66—67
Eosinophilia
in lymphoma, 228
F
in solid tumors, 228
Eosinophilic leukemia FAB classification, of leukemia
acute, 187-188 acute lymphoblastic, 159-161
chronic, 142-143 acute myeloid, 170-180
Epinephrine, in platelet aggregation Factor V Leiden mutation, activated
evaluation, 409-412 protein C resistance in, 392-395
Epstein-Barr virus infections, lymphoid Far-infrared spectroscopy, for blood
reactions in, 255—257 glucose measurement, 551
Epstein’s syndrome, 204 Fas ligand, in HIV neurotoxicity, 709
Eptifibatide, thrombocytopenia due to, Fasting plasma glucose test, 421-422
198-199
Fat redistribution, from antiretroviral
Erythrocytes. See Red cell(s). agents, 748-749
Erythrocytosis, in lymphoma, 227 Fatty acid binding protein, as myocardial
damage marker, 361
Erythroleukemia, 175
Fechtner syndrome, 204
Ethylenediamine tetraacetic acid,
pseudothrombocytopenia artifacts Fetus, HIV transmission to, 760-761
with, 83-85
Fever, viral hemorrhagic. See Viral
Expert systems, 515-528 hemorrhagic fevers; specific diseases.
1030 Subject Index | Clin Lab Med 22 (2002) 1021-1050
Fibrosis, bone marrow, in lymphoma, 225, Gene therapy, for HIV infection, 694
227
Genetic factors. See also Cytogenetics.
Filariasis, 271 in acute leukemia, 155-156
in group A streptococci virulence, 836
Filoviruses, 983. See also individual diseases.
in HIV infection, 763. See also
Fixation, of blood films, 11 Chemokine receptor CCRS.
progression of, 779-781
Flaviviruses, 979, 983. See also individual
diseases. Genetic markers, of liver dysfunction,
383-384
Flow cytometry
for differential count, 304-305 Genotypic assays, for HIV resistance,
for leukemia diagnosis, 156—157 637-638, 644
for lymphoma and leukemia diagnosis,
Giemsa stain, 19-20. See also
999 Wright-Giemsa stain.
for platelet function evaluation,
413-414 Glanzmann’s thrombasthenia, platelet
for reticulocyte count, 72 dysfunction in, 416-417
FLU OAI test, for influenza virus, 872 Glass effect, pseudoechinocytosis in, 94
Fluorescent treponemal antibody Glucocorticoid excess, in Cushing’s
absorption test, for syphilis, in donor syndrome, measurement of, 427-430
blood, 481
Glucose, blood, measurement of
Fluoroimmunoassay, time-resolved, for in diabetes mellitus diagnosis,
influenza virus, 873 421-422
in hypoglycemia, 423-425
Follicular lymphoma, 241-242
noninvasive, 550-553
Food and Drug Administration, blood
Glucose tolerance testing, 421-422
transfusion regulations of, 476
Glycogen phosphorylase, as myocardial
Foscarnet, for Kaposi’s sarcoma, 896
damage marker, 361
Fractalkine, neuroprotective effects of, in
Glycoprotein receptors
HIV infection, 712
antagonists to, platelet dysfunction
Free radical inhibitors, neuroprotective due to, 416
effects of, in HIV infection, 711 in platelet aggregation, 407
Free thyroxine, measurement of, in thyroid gp4l protein, HIV, in cell entry, 683, 685
dysfunction, 426-427
gp120 protein, HIV
French-American-British (FAB) in cell entry, 683-685
classification, of leukemia in neurotoxicity, 708-709
acute lymphoblastic, 159-161 recombinant, in vaccine preparation,
acute myeloid, 170-180 803-804
Fungal infections, blood film findings in, gp160 protein, HIV, recombinant, in
265-267 vaccine preparation, 803-804
Grabbing nonintegrin, dendritic cell-
specific, in HIV cell entry, 687-688
G
Gram stain, for donor blood bacterial
gag gene and protein, HIV, 612-614
detection, 484
in replication, 619-620
in vaccine preparation, 804-805 Granular acute lymphoblastic leukemia,
185
Gamma-glutamyltransferase, in cholestasis,
380-381, 386-387 Granulopoiesis, in solid tumors, 227-228
Ganciclovir, for Kaposi’s sarcoma, 896 Gray platelet syndrome, 203
platelet dysfunction in, 417
Gastrin test, for vitamin B;> deficiency, 441
versus pseudo gray platelet
Gene sequence analysis, for Bartonella, 949 syndrome, 87